Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients

An analysis of Phase 3 data presented by Biogen Inc BIIB and Eisai Co Ltd ESALY of its Alzheimer's therapy Aduhelm (aducanumab) showed the treatment slowed cognitive, functional, and behavioral decline in the early stages of the disease.
Treatment effects were exhibited across all three cognitive and three functional domains measured by Clinical Dementia Rating-Sum of Boxes (CDR-SB), the EMERGE study's primary endpoint.
Treatment effects were observed across Alzheimer's Disease Assessment Scale – Cognitive Subscale (ADAS-Cog13) items sensitive to cognitive change in early symptomatic Alzheimer's secondary endpoint measures.
Aduhelm was also associated with reducing behavioral and psychiatric symptoms of Alzheimer's disease, as measured by the Neuropsychiatric Inventory-10 (NPI-10), a tertiary endpoint.
Also, data analyses demonstrated a positive association between aducanumab treatment effect on brain amyloid-beta plaques and clinical measures across dose groups, except for the high-dose group.
A greater reduction in brain plaque levels was also associated with a greater reduction in cerebrospinal fluid (CSF) markers of tau and neurodegeneration and less decline on clinical endpoints.
Additionally, the third analysis showed that a smaller magnitude of clinical decline was observed in patients whose brain plaque levels were lowered to a threshold considered to be amyloid negative relative to patients who did not reach this threshold.
Price Action: BIIB shares closed at $331.93, and ESALY shares closed at 86.34 on Monday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga